Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems
Open accessThe DOI matches its Crossref record; 194 of the 195 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is an irreversible and progressive neurodegenerative disorder. Most existing treatments only provide symptomatic solutions. Here, we introduce currently available commercial drugs and new therapeutics, including repositioned drugs, to treat AD. Despite tremendous efforts, treatments targeting the hallmarks of AD show limited efficacy. Challenges in treating AD are partly caused by difficulties in penetrating the blood–brain barrier (BBB). Recently, nanoparticle (NP)-based systems have shown promising potential as precision medicines that can effectively penetrate the BBB and enhance the targeting ability of numerous drugs. Here, we describe how NPs enter the brain by crossing, avoiding, or disrupting the BBB. In addition, we provide an overview of the action of NPs in the microenvironment of the brain for the treatment of AD. Diverse systems, including liposomes, micelles, polymeric NPs, solid-lipid NPs, and inorganic NPs, have been investigated for NP drug loading to relieve AD symptoms, target AD hallmarks, and target moieties to diagnose AD. We also highlight NP-based immunotherapy, which has recently gained special attention as a potential treatment option to disrupt AD progression. Overall, this review focuses on recently investigated NP systems that represent innovative strategies to understand AD pathogenesis and suggests treatment and diagnostic modalities to cure AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of nanoparticles (NP), with sizes between 10 and 1000 nm, capable of encapsulating therapeutic molecules by targeting transport processes in the CNS, can improve the crossing of molecules through the BBB in neurological disorders and reach targeted brain regions [29,30,31].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Circumvention of the BBB via local routes can involve invasive procedures, such as intracerebroventricular and intrathecal ones, that deliver drugs directly into the CSF or brain tissue but remain inefficient and clinically restricted [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, prolonged BBB disruption associated with long-term treatment raises safety concerns, as it may facilitate neurotoxic effects in the brain [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because liposomes are made with lipids, they are biocompatible, biodegradable, and can fuse to cell membranes. Additionally, due to their size, fluidity, permeability, and composition, they are suitable for controlled drug release, while being versatile in the drug encapsulation, as they can encapsulate both lipophilic and hydrophilic drugs (dual solubility) [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, some molecules can cross the BBB by two main pathways, transcellular or paracellular, through the cell or the intercellular space, respectively [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This drug is designed to act on the deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain [6].”
Background2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · cited 1×
“The abnormal processing of amyloid precursor protein (APP) by β- and γ-secretases produces extracellular non-vascular accumulation of Aβ40 and Aβ42 peptides [22,23].”
BackgroundMicroglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 1×
“These latter preventive activities are supported by ApoE, which relies on TREM2 and activates microglia into the disease-associated microglia (DAM) state [174,175].”
BackgroundThe cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Research works printed but not linked: 1
- Gupta A. Chapter 21—Nanoemulsions Nanoparticles for Biomedical Applications Chung E.J. Leon L. Rinaldi C. Elsevier Amsterdam, The Netherlands 2020 371 384
Cited by
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
Levodopa-loaded nanoparticles for the treatment of Parkinson's disease
van Vliet, E. F., Knol, M. J., Schiffelers, R. M., Caiazzo, M., & Fens, M. H. A. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.026 · Cited by 97
Pei, J., Kumarasamy, R. V., Jayaraman, S., Kanniappan, G. V., Long, Q., & Palanisamy, C. P. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102665 · Cited by 97
Khalid-Salako, F. A., Khaligh, S. S., Fathi, F., Demirci, O. C., Öncer, N., Kurt, H., & Yüce, M. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c07366 · Cited by 83
Quantum dots: The cutting-edge nanotheranostics in brain cancer management
Chakraborty, P., Das, S. S., Dey, A., Chakraborty, A., Bhattacharyya, C., Kandimalla, R. J. L., Mukherjee, B., Gopalakrishnan, A. V., Singh, S. K., Kant, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.047 · Cited by 69
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
Nunes, D., Loureiro, J. A., & Pereira, M. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112296 · Cited by 68
Kaur, P., Khera, A., Alajangi, H. K., Sharma, A., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03164-z · Cited by 59
Weng, S., Lai, Q.-L., Wang, J., Zhuang, L., Cheng, L., Mo, Y., Liu, L., Zhao, Z., Zhang, Y., & Qiao, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.899944 · Cited by 47
Theranostics: Integrated Diagnostics and Therapy Using Nanomedicine
Singh, V. (2024) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-72467-1_17 · Cited by 52
Advancements in the Application of Nanomedicine in Alzheimer’s Disease: A Therapeutic Perspective
Puranik, N., Yadav, D., & Song, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814044 · Cited by 50
Shen, X., Li, H., Zhang, B., Li, Y., & Zhu, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199793 · Cited by 48
Recent Insights into the Neurobiology of Alzheimer’s Disease and Advanced Treatment Strategies
Anitha, K., Singh, M. K., Kohat, K., Varshini, T. S., Chenchula, S., Padmavathi, R., Amerneni, L. S., Vishnu Vardhan, K., Mythili Bai, K., Chavan, M. R., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04384-1 · Cited by 42
Razavi, Z. S., Razavi, F. S., & Alizadeh, S. S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117357 · Cited by 42
Nanoscale drug formulations for the treatment of Alzheimer's disease progression
Liqin, L., He, H., Du, B., & He, Y. (2025) · RSC Advances · doi:10.1039/d4ra08128e · Cited by 42
A Promising Approach: Magnetic Nanosystems for Alzheimer’s Disease Theranostics
Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092316 · Cited by 40
“CS NPs have some unique features, such as a mucoadhesive nature and intrinsic bioactivity, which can not only promote the penetration of drugs into the brain through the olfactory route but also represent anti-AD therapeutics themselves [91,92].”
BackgroundFar, B. F., Safaei, M., Pourmolaei, A., AdibAmini, S., Shirdel, S., Shirdel, S., Emadi, R., & Kaushik, A. K. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c00112 · Cited by 40
Recent Progress in Nanomedicine for the Diagnosis and Treatment of Alzheimer’s Diseases
Yang, H., Tan, H., Wen, H., Xin, P., Liu, Y., Deng, Z., Xu, Y., Gao, F., Zhang, L., Ye, Z., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c11966 · Cited by 39
The Role of Reactive Oxygen Species in Alzheimer's Disease: From Mechanism to Biomaterials Therapy
Yu, Z., & Luo, F. H. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304373 · Cited by 36
Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning
Kuznetsova, D. A., Gaynanova, G. A., Vasilieva, E. A., Pavlov, R. V., Zueva, I. V., Babaev, V. M., Kuznetsov, D. M., Voloshina, A. D., Petrov, K. A., Zakharova, L. Y., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091950 · Cited by 30
Alzheimer's Disease Diagnosis in the Preclinical Stage: Normal Aging or Dementia
Marvi, F., Chen, Y.-H., & Sawan, M. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2024.3376835 · Cited by 30
Fathian-Nasab, M.-H., Manavi, M. A., Gelivarisarshari, M., Daghighi, S. M., Beyer, C., Baeeri, M., & Sanadgol, N. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114909 · Cited by 29
Cáceres, C., Heusser, B., Garnham, A., & Moczko, E. (2023) · Cells · doi:10.3390/cells12232669 · Cited by 27
Sachdeva, P., Narayanan, K. B., Sinha, J. K., Gupta, S. K., Ghosh, S., Singh, K. K., Bhaskar, R., Almutary, A. G., Zothantluanga, J. H., Kotta, K. K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231181 · Cited by 26
Wang, Y., Zhu, J., Jia, W., Xiong, H., Qiu, W., Xu, R., & Lin, Y. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c14626 · Cited by 25
Li, F.-R., Yu, Y., Du, Y.-M., Kong, L., Liu, Y., Wang, J., Chen, M.-H., Liu, M., Zhang, Z., Li, X., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00625 · Cited by 24
Kiran, N. S., Vaishnavi, G., Singh, S. K., Yashaswini, C., Parihar, A., Pal, S., Kaur, J., Prajapati, B. G., Mohite, P. B., & Puri, A. V. (2024) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-024-00340-6 · Cited by 24
Ahmed, T. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16336 · Cited by 23
Dey, A., Ghosh, S., Rajendran, R. L., Bhuniya, T., Das, P., Bhattacharjee, B., Das, S., Mahajan, A. A., Samant, A., Anand, K., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179690 · Cited by 23
Boccardi, V., Poli, G., Cecchetti, R., Bastiani, P., Scamosci, M., Febo, M., Mazzon, E., Bruscoli, S., Brancorsini, S., & Mecocci, P. (2023) · Nutrients · doi:10.3390/nu15030634 · Cited by 21
Chromenone: An emerging scaffold in anti-Alzheimer drug discovery
Agarwal, U., Verma, S. K., & Tonk, R. K. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129912 · Cited by 21
Rouhi, N., Chakeri, Z., Ghorbani Nejad, B., Rahimzadegan, M., Rafi Khezri, M., Kamali, H., & Nosrati, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37533 · Cited by 20
Impact of Textile-Derived Micro- and Nanoplastics on Brain Health: An Emerging Environmental Risk
Bayattork, M., Rahman, M., Hossain, M. I., Zhang, Y., Haque, A. N. M. A., Kim, B., & Naebe, M. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.5c10338 · Cited by 20
Mitochondrial Ca2+ Signaling and Bioenergetics in Alzheimer’s Disease
Arnst, N., Redolfi, N., Lia, A., Bedetta, M., Greotti, E., & Pizzo, P. (2022) · Biomedicines · doi:10.3390/biomedicines10123025 · Cited by 20
Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets
Gu, X., Long, Q., Qi, Q., Zhou, J., Chen, S., & Wang, L. (2024) · BioScience Trends · doi:10.5582/bst.2023.01288 · Cited by 19
Recent Nanoscale Carriers for Therapy of Alzheimer's Disease: Current Strategies and Perspectives
Zakharova, L. Y., Gaynanova, G. A., Vasilieva, E. A., Vasileva, L. A., Pavlov, R. V., Kashapov, R. R., Petrov, K. A., & Sinyashin, O. G. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221115103513 · Cited by 18
Jeyaraman, M., Rajendran, R. L., Muthu, S., Jeyaraman, N., Sharma, S., Jha, S. K., Muthukanagaraj, P., Hong, C. M., da Fonseca, L. F., Lana, J. F., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17808 · Cited by 17
Wang, R., Peng, S., Zhu, J., Xu, Y., Wang, M., Zhang, L., Qiu, Y., Hou, D., Wang, Q., & Liu, R. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1651708 · Cited by 16
Menéndez‐González, M., Tamba, B.-I., Leclere, M., Mabrouk, M., Schreiner, T. G., Ciobanu, R. C., & Tomás‐Zapico, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030768 · Cited by 16
Rahman, M. A., Rahman, M. H., Rhim, H., & Kim, B. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240426091311 · Cited by 15
Wu, W., Huang, J., Han, P., Zhang, J., Wang, Y., Jin, F., & Zhou, Y. (2023) · Molecules · doi:10.3390/molecules28227631 · Cited by 15
Chitosan polyplexes for targeted gene delivery: From mechanisms to clinical applications
Joshi, R., Paliwal, T., Sharma, S. K., Kapoor, D. U., & Prajapati, B. G. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.124080 · Cited by 14
Sharma, D. K. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2561788 · Cited by 13
Tabish, M., Malik, I., Akhtar, A., & Afzal, M. F. (2025) · Biomolecules · doi:10.3390/biom15101405 · Cited by 11
Blood–brain barrier disruption in dementia: Nano‐solutions as new treatment options
Cooper, C. G., Kafetzis, K. N., Patabendige, A., & Tagalakis, A. D. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.16229 · Cited by 11
Chauhan, A., & Jain, S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128386983250410092649 · Cited by 10
Plant-based flavonoids and their nanoparticles: Latest arsenal against Alzheimer’s disease
Kumbhar, P., Kolekar, K. A., Vishwas, S., Kamble, V., Bashir, B., Patil, K. S., Bhagwat, D. A., Gupta, G., Prasher, P., Singh, M., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01906-9 · Cited by 10
Zahariev, N., Boyuklieva, R., Penkov, D., Lukova, P., & Katsarov, P. (2025) · Materials · doi:10.3390/ma18184302 · Cited by 10
Phytoactive drugs used in the treatment of Alzheimer’s disease and dementia
Soni, A. G., Verma, A., Joshi, R., Shah, K., Soni, D., Kaur, C. D., Saraf, S., & Chauhan, N. S. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03243-z · Cited by 10
Liu, D., Zhao, Y., Liu, R., Qiao, B., Lu, X., Bei, Y., Niu, Y., & Yang, X. (2025) · Medicine · doi:10.1097/md.0000000000041694 · Cited by 10
Management of Alzheimer's Disease With Nanotechnological Interventions and Novel Therapeutics
Shahrukh, M., Ahmad, S., Zaafar, M., Hasan, N., & Ahmad, F. J. (2025) · Drug Development Research · doi:10.1002/ddr.70120 · Cited by 9
Mancuso, R., Citterio, L. A., Agostini, S., Marventano, I., Rosa, F. L., Re, F., Seneci, P., Saresella, M., & Clerici, M. (2023) · Pharmaceuticals · doi:10.3390/ph16111590 · Cited by 9
Sub-chronic oral toxicity of a water-soluble extract of Centella asiatica (Centell-S) in Wistar rats
Junsai, T., Tangpanithandee, S., Srimangkornkaew, P., Suknuntha, K., Vivithanaporn, P., & Khemawoot, P. (2024) · Food and Chemical Toxicology · doi:10.1016/j.fct.2024.114509 · Cited by 9
Nanoparticles as an Encouraging Therapeutic Approach to Alzheimer’s Disease
Batko, J., Antosz, K., Nowakowska, H., Błażejewska, M., Kowalik, E. M., Beszłej, J. A., & Leszek, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167725 · Cited by 9
The therapeutic efficacy of nanoparticles in the treatment of alzheimer’s disease
Ntondini, T. L., Naki, T., & Alven, S. (2025) · Acta Neurologica Belgica · doi:10.1007/s13760-025-02905-w · Cited by 8
Nose to brain drug delivery through advanced drug delivery systems
Kumar, R., Singh, A., Kapoor, B., Hussain, M. S., Singh, S. K., Dua, K., Dureja, H., Thomas, N. V., & Gulati, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00001-9 · Cited by 7
Rawat, E., Sharma, S., Vyas, S., Alsaidan, O. A., Kapoor, D. U., & Prajapati, B. G. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125851 · Cited by 7
Recent Advances of Carbon dots for Treatment of Alzheimer’s and Parkinson’s Diseases
Vedhanayagam, M. (2023) · International Journal of Advanced Nano Computing and Analytics · doi:10.61797/ijanca.v2i1.240 · Cited by 6
Kurtukova, V., Aktas, S., Pupure, J., Narbute, K., Muceniece, R., & Piļipenko, V. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05079-x · Cited by 6
Trends in Nanoparticle-based Strategies for the Management of Neuroinflammation
Rana, A., Malviya, R., Rajput, S., Sridhar, S. B., & Wadhwa, T. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273373041250707012835 · Cited by 6
Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 7
TEODORO, A. L. S., Ramada, M. H. S., Paciencia, M. L. B., Dohms, S. M., Câmara, P. E. A. S., Varella, A. D., Frana, S. A., Silva, J. D. S., & Suffredini, I. B. (2024) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202420240678 · Cited by 6
Anti-amyloidogenic properties of 5‑caffeoylquinic acid-capped selenium nanoparticles
Shirsat, S. D., Li, C., Liu, Z., Achal, V., & Habimana, O. (2025) · Scientific Reports · doi:10.1038/s41598-025-03962-0 · Cited by 6
Breaking Barriers in Alzheimer’s Disease: the Role of Advanced Drug Delivery Systems
Shekho, D., Mishra, R., Kamal, R., Bhatia, R., & Awasthi, A. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02923-6 · Cited by 6
Elbermawy, Y., El-Desouky, S., Arafa, R. K., Elfarrash, S., & Bassiouny, A. R. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05534-9 · Cited by 5
Wang, M., Yang, X., Gao, Y., & Han, W. (2023) · Foods · doi:10.3390/foods12030635 · Cited by 5
Exploring Nanomedicine Ventures and Latest Developments in Clinical Trials
Patil, U. D. (2024) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-72467-1_16 · Cited by 4
Singh, K., Gupta, J. K., Lakhchora, G., Jain, D., Bhatt, A., Sharma, M. C., Chaitanya, M., & Tabish, M. (2025) · Current Alzheimer Research · doi:10.2174/0115672050380959250530112247 · Cited by 4
Shen, S., He, J., Song, S., Jiang, C., Li, J., Peng, S., Shen, C., & Zou, Q. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.167028 · Cited by 4
Nanomaterials: an overview of current trends and future prospects in neurological disorder treatment
Eshak, D., & Arumugam, M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06877-6 · Cited by 4
Recent Advances in the Non-viral Delivery of Genes to Central Nervous System Disorders
Marei, H. E. S. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01703-z · Cited by 4
From Molecular Networks to Medicines: Targeting Complexity in Alzheimer’s Disease (AD) Therapy
Kumar, R. P., Patel, S., Mishra, P. S., Srivastava, S., Sridhar, S. B., Shareef, J., Sahu, R., Tariq, M., Uddin, J., & Muhsinah, A. B. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05909-6 · Cited by 4
Biswal, B., Satapathy, B. S., Mishra, A., Maharana, L., & Pattnaik, S. (2025) · Current Drug Discovery Technologies · doi:10.2174/0115701638329824241220055621 · Cited by 4
Singh, B., Singh, K., Gupta, J. K., Semwal, B. C., Jain, D., & Sharma, M. C. (2025) · Current Alzheimer Research · doi:10.2174/0115672050386924250930184405 · Cited by 4
Pharmacokinetics and pharmacodynamics of various novel formulations targeting Alzheimer's disease
Gawade, A. R., Polshettiwar, S. A., Hingalajia, H., Prajapati, B. G., & Singh, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00027-3 · Cited by 4
Uttarkar, A., Rao, V., Bhat, D., & Niranjan, V. (2024) · Journal of Molecular Modeling · doi:10.1007/s00894-024-05860-0 · Cited by 4
Patne, A. Y., Bagban, I., & Suryawanshi, M. V. (2025) · BioChem · doi:10.3390/biochem5040040 · Cited by 3
Novel Therapeutic Approaches in Alzheimer's Disease
Ingle, P. V., Lee, Y. L., Wong, X. Y., Tan, S. P., Lim, E. J., Chin, M. Y., Zhen, M. C. S., Safian, N. H. B., & Hatware, K. V. (2024) · Current Drug Therapy · doi:10.2174/0115748855332142240830114503 · Cited by 3
Niazi, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810211 · Cited by 3
Dendrimeric polymers-based nanobiosystems for targeted drug delivery
Mishra, V. K., Chattaraj, A., Kumar, B., & Mishra, Y. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-90254-0.00001-5 · Cited by 3
Attenuation Of Age-Related Cognitive Decline And Memory Deficits Through Apomorphine Administration
Ikram, H., Zakir, R., & Haleem, D. J. (2024) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2024.37.4.reg.829-838.1 · Cited by 3
Maisuradze, N., Kekutia, S., Markhulia, J., Tsertsvadze, T., Mikelashvili, V., Saneblidze, L., Chkhaidze, N., Horváth, Z. E., Almásy, L., & Mitskevichi, N. (2024) · Journal of Functional Biomaterials · doi:10.3390/jfb15120364 · Cited by 3
Silva, R., Monteiro, J., Ramalho, M. J., Andrade, S., Loureiro, J. A., & Pereira, M. C. (2026) · Pharmaceuticals · doi:10.3390/ph19050685 · Cited by 2
“PLGA NPs’ popularity is attributed to their unique particularities: controlled and sustained release profile, low toxicity, biocompatibility with cells and tissues, easy production, and approval by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) [14,23].”
InfluentialSurface engineered nano architectonics: An evolving paradigm for tackling Alzheimer's disease
Negi, M., Amulya, E., Phatale, V., Abraham, N., Hedaoo, A., Srinivasarao, D. A., & Srivastava, S. K. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123155 · Cited by 2
Functionalized Nanomaterials for Drug Delivery
George, N., Janiyani, K., Ogoe, M., Gupta, A., Safo, K. K., Singh, H., & Pandya, S. R. (2025) · Series in bioengineering · doi:10.1007/978-981-95-0457-2_3 · Cited by 2
Latina, V., Soligo, M., Ros, T. D., Schifano, E., Guarnieri, M., Montanari, A., Amadoro, G., & Fiorito, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210844 · Cited by 2
Effective Brain Targeting Using the Self-Emulsifying Drug Delivery Systems
Gawde, S., Bachhav, Y. G., & Kumar, M. S. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03398-3 · Cited by 2
Shah, D., Akarte, K., Patel, S., Patel, A., Kushwaha, N., Panjwani, D., Patel, V. A., Ahlawat, P., & Shah, A. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05835-7 · Cited by 2
Khozani, M. S., Palizvan, M. R., Mosayebi, G., Ganji, A., & Ghazavi, A. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02163-z · Cited by 2
Bhukta, P., Sahu, P. K., & Acharya, B. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100495 · Cited by 2
Singh, J., Sharma, S., Singh, R., & Singh, P. (2026) · Neuroscience Research and Clinical Practice · doi:10.64229/cztyf245 · Cited by 2
Implementation of Nanocarriers for Brain-Specific Drug Delivery System
Sharma, A., Alam, A., & Kaur, A. (2023) · Current Nanomaterials · doi:10.2174/2405461508666230804102333 · Cited by 2
Ashour, M. N., Elias, T. R., Rasheed, W. I., El-Toukhya, S., Youness, E. R., Sleem, A. A., ramadan, M. M., Mahmoud, K. F., Yassen, N. N., Abdel-Monem, M., et al. (2024) · Egyptian Journal of Chemistry · doi:10.21608/ejchem.2024.251449.8997 · Cited by 2
Advances in Nanotechnology for Targeted Drug Delivery in Alzheimer's Disease
Maheshwari, S., Kumar, P., Dwivedi, V., Mishra, A., Singh, V. K., & Singh, A. V. (2025) · Current Aging Science · doi:10.2174/0118746098359258250727103551 · Cited by 2
Yashwanth, S., Shivakumar, H., Arpitha, N., Yadav, T. B., & S, L. P. N. (2025) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2025/v22i3479 · Cited by 1
Blood Brain Barrier and Nanotechnology for Neurodegenerative Disorders
Tripathi, S. M., Mishra, S. K., Malviya, R., & Ojha, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324846125010007 · Cited by 1
Talebian, A., Zare, P., Barfei, M., Darbi, S. Z. M., Bagheri, A. M., & Ranjbar, M. (2025) · The Neuroscience Journal of Shefaye Khatam · doi:10.61186/shefa.13.2.69 · Cited by 1
Dendrimers: Advancing Therapeutic Strategies for Dementia
Singh, A., Maheshwari, S., Ansari, V. A., Verma, A., Mahmood, T., Akhtar, J., Ahsan, F., Vishwakarma, V. K., & Wasim, R. (2025) · Current Aging Science · doi:10.2174/0118746098343913250818112618 · Cited by 1
Baher, N. K., Heikal, L., El-Salamouni, N. S., Gaafar, P. M. E., Bakr, B. A., Badae, N. M., & ElGamal, S. S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107925 · Cited by 1
Yadav, S., Pandey, S. K., & Awasthi, S. (2026) · Advanced Therapeutics · doi:10.1002/adtp.202500576 · Cited by 1
Manseur, A., Hanini, K., Tamfu, A. N., Boudiba, L., Eroğlu, B., Küçükaydın, M. T., Ceylan, Ö., Benahmed, M., & Boudiba, S. (2026) · Natural Sciences · doi:10.1002/ntls.70066 · Cited by 1
Metadata
- Authors
- Poudel, P., & Park, S.
- Affiliations
- Keimyung University (KR)
- Corresponding author
- Park, Soyeun
- ORCID
- Park, Soyeun
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-04-11
- Volume
- 14
- Issue
- 4
- Pages
- 835
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9026997
- OpenAlex
- W4223478480
- Cited by
- 124
- References
- 195
- Citations by year
- 2026: 28 · 2025: 37 · 2024: 33 · 2023: 17 · 2022: 9
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Keimyung University (2019)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- Alzheimer's disease, nanoparticle drug delivery, blood-brain barrier, liposomes, micelles, polymeric nanoparticles, solid lipid nanoparticles, inorganic nanoparticles, Alzheimer's disease therapeutics, Alzheimer's disease diagnosis, neurodegeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.